Applied Therapeutics Stock Forecast, Price & News

-0.68 (-3.74 %)
(As of 07/27/2021 04:45 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume85,296 shs
Average Volume108,384 shs
Market Capitalization$456.94 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive APLT News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Applied Therapeutics logo

About Applied Therapeutics

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.91 out of 5 stars

Medical Sector

762nd out of 2,218 stocks

Pharmaceutical Preparations Industry

367th out of 869 stocks

Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Applied Therapeutics (NASDAQ:APLT) Frequently Asked Questions

Is Applied Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Applied Therapeutics stock.
View analyst ratings for Applied Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Applied Therapeutics?

Wall Street analysts have given Applied Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Applied Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Applied Therapeutics' next earnings date?

Applied Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Applied Therapeutics

How were Applied Therapeutics' earnings last quarter?

Applied Therapeutics, Inc. (NASDAQ:APLT) issued its quarterly earnings data on Monday, May, 10th. The company reported ($1.00) EPS for the quarter, topping the Zacks' consensus estimate of ($1.01) by $0.01.
View Applied Therapeutics' earnings history

How has Applied Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Applied Therapeutics' stock was trading at $29.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, APLT stock has decreased by 40.8% and is now trading at $17.52.
View which stocks have been most impacted by COVID-19

What price target have analysts set for APLT?

3 brokerages have issued 1 year price objectives for Applied Therapeutics' stock. Their forecasts range from $18.00 to $85.00. On average, they anticipate Applied Therapeutics' stock price to reach $45.50 in the next twelve months. This suggests a possible upside of 159.7% from the stock's current price.
View analysts' price targets for Applied Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Applied Therapeutics' key executives?

Applied Therapeutics' management team includes the following people:
  • Dr. Shoshana Shendelman Ph.D., Chair of the Board of Directors, Founder, Pres, CEO & Sec. (Age 42, Pay $895.12k)
  • Dr. Charles Silberstein M.D., CFA, CFO & Head of Bus. Devel. (Age 50, Pay $378.2k) (LinkedIn Profile)
  • Dr. Riccardo Perfetti, Chief Medical Officer (Age 62, Pay $672.14k) (LinkedIn Profile)
  • Mr. Chids Mahadevan, VP of Fin. & Chief Accounting Officer (Age 52)
  • Mr. Adam Hansard, Chief Commercial Officer (Age 45)

Who are some of Applied Therapeutics' key competitors?

What other stocks do shareholders of Applied Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Enterprise Products Partners (EPD), Pfizer (PFE), Advanced Micro Devices (AMD), Energy Transfer (ET), Micron Technology (MU), NVIDIA (NVDA), Verizon Communications (VZ), AbbVie (ABBV), The Walt Disney (DIS) and Raytheon Technologies (RTX).

When did Applied Therapeutics IPO?

(APLT) raised $60 million in an IPO on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank served as the underwriters for the IPO and Baird was co-manager.

What is Applied Therapeutics' stock symbol?

Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT."

How do I buy shares of Applied Therapeutics?

Shares of APLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Applied Therapeutics' stock price today?

One share of APLT stock can currently be purchased for approximately $17.52.

How much money does Applied Therapeutics make?

Applied Therapeutics has a market capitalization of $456.92 million. The company earns $-93,960,000.00 in net income (profit) each year or ($4.28) on an earnings per share basis.

How many employees does Applied Therapeutics have?

Applied Therapeutics employs 24 workers across the globe.

What is Applied Therapeutics' official website?

The official website for Applied Therapeutics is

Where are Applied Therapeutics' headquarters?

Applied Therapeutics is headquartered at 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173.

How can I contact Applied Therapeutics?

Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company can be reached via phone at 212-220-9226 or via email at [email protected]

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.